B
ronchioloalveolar carcinoma (BAC) may be distinguished from other adenocarcinomas of the lung by unique histology, radiology, molecular biology, and clinical course. It is thought that the course of patients with BAC is more indolent than in persons with other non-small-cell lung cancer (NSCLC) histologies. Although "pure" BAC is defined explicitly by the World Health Organization (WHO), 1 there are many more patients whose adenocarcinomas have features of BAC, making the histologic classification of such tumors uncertain. 2 Several clinical trials have been performed specifically in patients with BAC, based on the notion that these tumors may be somewhat less sensitive to standard chemotherapy and that the biology of BAC differs from that of other adenocarcinomas.
MATERIALS AND METHODS
This conference group reviewed results of patients with BAC included in trials studying patients with NSCLC in general and five studies designed specifically for persons with BAC, testing paclitaxel, gefitinib, and erlotinib. Local treatment approaches are also outlined here, including inhalational therapy with investigational anticancer agents. The conference group made recommendations for clinical trial design and further research in BAC.
RESULTS

Results in Patients with BAC Included in ECOG Trial 1594 in Patients with Advanced NSCLC
The Eastern Cooperative Oncology Group (ECOG) studied four platinum-based regimens as initial therapy for patients with NSCLC. 3 This study included 1163 patients, 17 of whom were classified as having BAC by the investigator. The response rate in patients with BAC was 6% compared with 20% for patients with other types of NSCLC. Median The Southwest Oncology Group (SWOG) conducted the first prospective trial for patients with BAC. 4 Patients in this trial had ECOG performance status 0 to 2 and stage IIIB/IV BAC as determined by the treating institution. All 58 patients received paclitaxel 35 mg/m 2 /day continuously infused for 96 hours every 21 days. The partial response rate was 14%. Median overall survival was 12 months, and the 3-year survival rate was 13%. Because of a high treatmentrelated death rate (9%, 5/58), this regimen was not pursued. However, this trial demonstrated the feasibility of conducting prospective trials in patients with BAC in a cooperative group setting and established benchmarks for future studies.
Paclitaxel by 3-hour Infusion for Patients with BAC (EORTC 08956)
The European Organization for Research and Treatment of Cancer Lung Cancer Group studied a 3-hour paclitaxel infusion in patients with stage IIIB/IV BAC. 5 Nineteen patients received paclitaxel 200 mg/m 2 every 21 days. Two partial responses were confirmed (response rate of 11% (95% CI, 1 to 35%). The median survival was 9 months, and the 1-year survival rate was 35% (95% CI, 14 to 56%). The study was terminated because of a low response rate.
Gefitinib (Iressa) for Patients with BAC (SWOG 0126)
SWOG S0126 evaluated 500 mg of gefitinib per day. 6 The study was undertaken based on the detection of epidermal growth factor receptor (EGFR) protein in BAC tumors collected from S9714, the activity seen in patients with NSCLC in phase I trials of gefitinib, and reports of rapid and durable responses in patients with BAC. 7, 8 This study enrolled 55 patients with eligibility identical to the preceding S9714 trial along with 35 previously treated patients. All had performance status of 0 to 2 and stage IIIB/IV BAC as determined by the treating institution. Approximately one third of patients had a dose reduction to 250 mg based on toxicities, and 11% discontinued therapy. Three patients developed increasing pulmonary infiltrates and hypoxemia requiring treatment with steroids, antibiotics, and supplemental oxygen after discontinuing gefitinib. Each of these patients died of what was possibly treatment-related interstitial lung disease, although disease progression, infection, or other causes may have contributed. Among patients with measurable disease, gefitinib response rates (RECIST) were 19 and 9% for chemo-naïve and chemo-pretreated patients, respectively. Complete responses were seen. The median survival of untreated patients was 12 months, similar to that in SWOG 9714. Several patients had progression-free survival of more than a year, something not observed with paclitaxel. The survival at 2 and 3 years was 38 and 23%, an improvement on the 29 and 13% seen in S9714. Patients with nonmucinous BAC had superior survival on gefitinib compared with those with the same histologic features treated with paclitaxel on protocol S9714 discussed above. 9 Increased EGFR gene copy number detected by fluorescence in situ hybridization was associated with improved survival. 10 Correlations of clinical outcomes with EGFR protein expression measured by immunohistochemistry and EGFR mutations are ongoing.
Erlotinib (Tarceva) for Patients with BAC
During the early testing of erlotinib, dramatic responses were observed in patients with BAC. To follow up on this lead, four centers undertook a phase II trial of erlotinib 150 mg daily in patients with BAC-both "pure BAC" as defined by the WHO and adenocarcinoma with BAC features. 2, 11 A total of 159 patients with stage IIIB or IV inoperable NSCLC had central review of biopsy specimens. BAC was identified in 66% of submitted specimens. Like the SWOG studies, pathological eligibility was determined by the reading from the pathology department where the patient was treated, not by central review. One hundred one patients were treated; 67% of the patients were women, and 22% had previously received chemotherapy. Central pathology review showed that 12% were "pure BAC" and that 88% had adenocarcinoma with BAC features. Twenty-five percent of the patients had never been smokers. A final report is planned for the first half of 2006.
Erlotinib treatment led to partial responses (RECIST criteria) in 20 of the 84 patients evaluated at the time of the report (24%; 95% CI, 16 to 34%). The partial response rate was 40% in never smokers and 19% in current or former smokers. The 1-year survival rate rfor all patients was 58%; the median survival rate has not yet been determined. There was one case of interstitial lung disease resulting in treatment-related death. EGFR exons 18 to 24 have been sequenced in 19 tumor specimens to date. Among nine patients with partial responses, six had EGFR mutations, two with deletions in exon 19, and four had substitution mutations in exon 21 (L858R). 12 
Other Strategies Adenovirus P53 Administered by Bronchioloalveolar Lavage in Patients with BAC
Because BAC is characterized by thin sheets of tumor cells growing along the airways, agents delivered by inhalation should have direct access to the tumor. A phase I study of p53 gene transfer using an adenovirus vector (Ad-p53; RPR/INGN 201) delivered via bronchioloalveolar lavage (BAL) to involved lobes of the lung was conducted at the University of Wisconsin and Vanderbilt University. 15 Treatments consisted of two BAL at the same dose level given 2 weeks apart to a single involved lobe. Additional treatment to all involved lobes was allowed if initial treatments were tolerated. The initial dose was 2 ϫ 10 9 viral particles per dose, escalated in 10-fold increments. Among 14 patients registered, grade 4 pulmonary toxicity was noted at the 2 ϫ 10 9 dose level. Two additional patients at this level did not suffer a dose-limiting toxicity. After the completion of two cycles, pathologic response was noted on rebiopsy in two patients, four of nine patients showed improved diffusing capacity, and four of 11 had symptomatic improvement.
Autologous Antitumor Vaccine GVAX (CG8123)
GVAX (CG8123) (Cell Genesys, Inc.) is a GM-CSF gene-modified autologous tumor cell vaccine that has shown antitumor activity in patients with NSCLC and, specifically, BAC. 16, 17 Despite these reports, no trials of this construct are planned for patients with BAC.
Inhalational Therapy: Interferon-␣, Doxorubicin, Cisplatin, and Indomethacin
A number of phase II trials and case reports of inhaled therapy have been described, with endpoints of tumor control and palliation of bronchorrhea. Ten patients with locally advanced BAC were treated with interferon-alpha as an inhaled aerosol with initial doses from 1 to 10 million units three times weekly and escalated to 20 million units daily. 18 No symptomatic or radiographic responses were seen. Aerosolized doxorubicin has been administered to patients with primary and secondary pulmonary malignancies, including six with NSCLC and at least one with BAC. Efficacy data have not yet been reported. 19 
Bronchorrhea: A Defining Symptom of BAC
Bronchorrhea, defined as the production of sputum of Ͼ100 ml/day, is a defining symptom of BAC. Seen in about 5% of patients, bronchorrhea causes substantial discomfort. Successful treatment of BAC eliminates this condition. A variety of treatments directed at this symptom have been studied, including inhaled indomethacin, 20, 21 oral and inhaled corticosteroids, 22 and macrolide antibiotics. 23, 24 Gefitinib inhibits mucin production 25 and decreases bronchorrhea. 26 -29 
Response Assessment in BAC Trials
Because of the diffuse nature of the pulmonary lesions often characteristic of BAC, some investigators have suggested that standard methods for response assessment may be inadequate for phase II trials conducted specifically in patients with BAC. Despite these concerns, the current standard of care includes patients with BAC in trials of NSCLC in general and routinely employs standard bidimensional or unidimensional response assessment. In addition, all four multicenter phase II trials completed exclusively in patients with BAC used standard criteria and reported no difficulties assessing response by both bidimensional 4, 5 and unidimensional 6 
Research Areas
• A trial of initial gefitinib or erlotinib, then a platinumbased doublet versus an initial platinum-based doublet, and then gefitinib or erlotinib • Exploration of the use of gefitinib and erlotinib both before and after surgery • Trials of BAC-specific targeted therapies must include determination of molecular correlates for the target of interest • Special areas to be addressed in clinical trials of systemic therapies in BAC:
• Central pathology review • Response assessment • Smoking history • Prior and comorbid pulmonary diseases.
• Proposed or in-progress studies:
• Phase II trial of weekly bortezomib (Velcade) as first-or second-line treatment (conducted by the California Cancer Consortium) • Phase II trial of twice-weekly bortezomib (Velcade) as first-or greater-line treatment (conducted by Millennium Pharmaceuticals) • Phase II trial of pemetrexed (Alimta) as first-or secondline treatment (conducted by SWOG) • Phase II trial of cetuximab (Erbitux) as first-or secondline treatment (conducted By ECOG).
• Phase II IFCT 05-04 trial: effect of an early therapeutic permutation on the tumoral control of patients receiving in the first line a specific inhibitor of tyrosin kinase of EGFR (erlotinib) or a taxane-based chemotherapy (paclitaxel ϩ carboplatin) for the treatment of nonresectable adenocarcinoma with bronchioloalveolar features.
